German Accelerator Life Sciences (GALS) - Advise, Connect, Inspire

German Accelerator Life SciencesGerman Accelerator Life Sciences (GALS) helps young German life science companies succeed in the global market. GALS provides individualized and highly flexible services, tailored towards the specific needs and objectives of startups and emerging companies in the life sciences. Experienced mentors and consultants work with the participating teams to establish networks of potential clients, partners, and investors.

Applicants must be promising emerging life science companies that have great potential to benefit from the GALS program. Companies must have an affiliation with Germany, i.e. incorporated in Germany or with significant operations there. Applicants must develop a product or service in (at least) one of the five supported life science segments: Digital Health, Medical Devices, Diagnostics, Therapeutics, or Platform Technologies. The stage of the company's growth is relevant; the age of the company is not.

Application
The GALS application consists of around 20 questions about your company, team, technology, and business plan. It only takes a couple of hours to complete. We also request that companies submit additional materials with their application, such as a slide deck and a product demo (if available). Companies apply to the GALS program via the F6S platform.

GALS accepts companies into the program on a rolling basis. Companies can apply any time. Applications are reviewed by the Selection Committee every 6-8 weeks. Program start dates are flexible.

Next application deadline: March 31, 2017

The GALS Selection Committee meets approximately every 6-8 weeks to evaluate new applications. GALS then invites selected promising companies to an in-person workshop for a further assessment of their technology/approach and business strategy.

All services provided by GALS are free of charge for program participants, however GALS will not cover any related travel or living expenses.

For further infromation, please visit:
http://germanaccelerator.com/life-sciences/

About the German Accelerator Life Sciences
The German Accelerator Life Sciences (GALS) is an initiative of the German Federal Ministry for Economic Affairs and Energy (BMWi), with the goal of helping German startups and young companies succeed in the global marketplace. GALS offers support in multiple areas, from free office space in the world's leading life science innovation hub, to mentoring and advising from industry experts and experienced leaders. GALS opened its doors in October 2015 and has its headquarters in Cambridge, Massachusetts.

Most Popular Now

European Artificial Intelligence Act Com…

The European Artificial Intelligence Act (AI Act), the world's first comprehensive regulation on artificial intelligence, enters into force. The AI Act is designed to ensure that AI developed and used...

Patient Safety must be Central to the De…

An EPR system brings together different patient information in one place, making it easier to access for healthcare professionals. This information can include patients' own notes, test results, observations by...

ChatGPT Shows Promise in Answering Patie…

The groundbreaking ChatGPT chatbot shows potential as a time-saving tool for responding to patient questions sent to the urologist's office, suggests a study in the September issue of Urology Practice®...

Survey: Most Americans Comfortable with …

Artificial intelligence (AI) is all around us - from smart home devices to entertainment and social media algorithms. But is AI okay in healthcare? A new national survey commissioned by...

AI Spots Cancer and Viral Infections at …

Researchers at the Centre for Genomic Regulation (CRG), the University of the Basque Country (UPV/EHU), Donostia International Physics Center (DIPC) and the Fundación Biofisica Bizkaia (FBB, located in Biofisika Institute)...

Video Gaming Improves Mental Well-Being

A pioneering study titled "Causal effect of video gaming on mental well-being in Japan 2020-2022," published in Nature Human Behaviour, has conducted the most comprehensive investigation to date on the...

New Diabetes Research Links Blood Glucos…

As part of its ongoing exploration of vocal biomarkers and the role they can play in enhancing health outcomes, Klick Labs published a new study in Scientific Reports - confirming...

Machine learning helps identify rheumato…

A machine-learning tool created by Weill Cornell Medicine and Hospital for Special Surgery (HSS) investigators can help distinguish subtypes of rheumatoid arthritis (RA), which may help scientists find ways to...

New AI Software could Make Diagnosing De…

Although Alzheimer's is the most common cause of dementia - a catchall term for cognitive deficits that impact daily living, like the loss of memory or language - it's not...

A New AI Tool for Cancer

Scientists at Harvard Medical School have designed a versatile, ChatGPT-like AI model capable of performing an array of diagnostic tasks across multiple forms of cancers. The new AI system, described Sept...

Vision-Based ChatGPT Shows Deficits Inte…

Researchers evaluating the performance of ChatGPT-4 Vision found that the model performed well on text-based radiology exam questions but struggled to answer image-related questions accurately. The study's results were published...

Bayer Launches New Healthy-Aging Ecosyst…

Combining a scientifically formulated dietary supplement, a leading-edge wellness companion app, and a saliva-based a biological age test by Chronomics, Bayer is taking a big step in the emerging healthy-aging...